Response To: “A Somatization Comorbidity Phenotype Impacts Response to Therapy in Rheumatoid Arthritis: Post Hoc Results From the Certolizumab Pegol Phase 4 PREDICT Trial”
Arthritis Research & Therapy
doi 10.1186/s13075-019-1848-4
Full Text
Open PDFAbstract
Available in full text
Date
February 20, 2019
Authors
Publisher
Springer Science and Business Media LLC